ORKA Key Statistics, Chart & Performance
The current stock price of ORKA is 30.84 USD. In the past month the price increased by 9.05%. In the past year, price increased by 45.47%.
ORKA Latest News, Press Relases and Analysis
ORKA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About ORKA
Company Profile
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 28 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Company Info
ORUKA THERAPEUTICS INC
855 Oak Grove Ave., Suite 100
Menlo Park CALIFORNIA US
Employees: 28
Phone: 16506067910
ORUKA THERAPEUTICS INC / ORKA FAQ
What does ORKA do?
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 28 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
What is the stock price of ORUKA THERAPEUTICS INC today?
The current stock price of ORKA is 30.84 USD. The price decreased by -0.29% in the last trading session.
Does ORKA stock pay dividends?
ORKA does not pay a dividend.
What is the ChartMill rating of ORUKA THERAPEUTICS INC stock?
ORKA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for ORKA stock?
18 analysts have analysed ORKA and the average price target is 47.75 USD. This implies a price increase of 54.85% is expected in the next year compared to the current price of 30.84.
Can you provide the PE ratio for ORKA stock?
ORUKA THERAPEUTICS INC (ORKA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).
ORKA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ORKA. When comparing the yearly performance of all stocks, ORKA is one of the better performing stocks in the market, outperforming 95.03% of all stocks.
ORKA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORKA. ORKA has a great financial health rating, but its profitability evaluates not so good.
ORKA Financial Highlights
Over the last trailing twelve months ORKA reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 66.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.96% | ||
| ROE | -20.88% | ||
| Debt/Equity | 0 |
ORKA Forecast & Estimates
18 analysts have analysed ORKA and the average price target is 47.75 USD. This implies a price increase of 54.85% is expected in the next year compared to the current price of 30.84.